The role of insulin as an antithrombotic humoral factor

• DOI: 10.1002/bies.10375
• Publication Date: 2003-12-24T09:00:30Z
• Authors: Kushal Chakraborty; Asru K. Sinha
• Keywords: Blood Platelets; 2. Zero hunger; Platelet Aggregation; Myocardial Ischemia; Down-Regulation; Thrombosis; Nitric Oxide; Receptors, Epoprostenol; Epoprostenol; Models, Biological; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Animals; Humans; Insulin

AbstractInsulin is well known for its essential role in carbohydrate metabolism: insulin deficiency results in the development of diabetes mellitus. It has been known for many years that people with diabetes mellitus are predisposed to develop thrombotic diseases including myocardial infarction. It was thought that the thrombus formation was the consequence of impaired carbohydrate metabolism. In recent years, it has become apparent that insulin is capable of ameliorating several pathophysiological events, leading to the inhibition and dissolution of the formed thrombus in the system. These insulin‐induced events include inhibition of platelet aggregation by prompting the synthesis of NO in platelet and prostacyclin in endothelial cells. Furthermore, insulin upregulates prostacyclin receptors and downregulates α2 adrenergic receptor in platelets, thereby amplifying the inhibition of platelet aggregation. Insulin also releases tissue plasminogen activator, a potent thrombolytic enzyme, from the platelet membrane which dissolves the formed thrombus leading to the resumption of normal blood circulation. In effect, insulin could be an essential tool in the control of thrombotic disorders. BioEssays 26:91–98, 2004. © 2003 Wiley Periodicals, Inc.